Article ; Online: Circuit imaging biomarkers in preclinical and prodromal Parkinson's disease.
Molecular medicine (Cambridge, Mass.)
2021 Volume 27, Issue 1, Page(s) 111
Abstract: Parkinson's disease (PD) commences several years before the onset of motor features. Pathophysiological understanding of the pre-clinical or early prodromal stages of PD are essential for the development of new therapeutic strategies. Two categories of ... ...
Abstract | Parkinson's disease (PD) commences several years before the onset of motor features. Pathophysiological understanding of the pre-clinical or early prodromal stages of PD are essential for the development of new therapeutic strategies. Two categories of patients are ideal to study the early disease stages. Idiopathic rapid eye movement sleep behavior disorder (iRBD) represents a well-known prodromal stage of PD in which pathology is presumed to have reached the lower brainstem. The majority of patients with iRBD will develop manifest PD within years to decades. Another category encompasses non-manifest mutation carriers, i.e. subjects without symptoms, but with a known mutation or genetic variant which gives an increased risk of developing PD. The speed of progression from preclinical or prodromal to full clinical stages varies among patients and cannot be reliably predicted on the individual level. Clinical trials will require inclusion of patients with a predictable conversion within a limited time window. Biomarkers are necessary that can confirm pre-motor PD status and can provide information regarding lead time and speed of progression. Neuroimaging changes occur early in the disease process and may provide such a biomarker. Studies have focused on radiotracer imaging of the dopaminergic nigrostriatal system, which can be assessed with dopamine transporter (DAT) single photon emission computed tomography (SPECT). Loss of DAT binding represents an effect of irreversible structural damage to the nigrostriatal system. This marker can be used to monitor disease progression and identify individuals at specific risk for phenoconversion. However, it is known that changes in neuronal activity precede structural changes. Functional neuro-imaging techniques, such as |
---|---|
MeSH term(s) | Animals ; Biomarkers/blood ; Brain/metabolism ; Brain/pathology ; Cerebrovascular Circulation ; Diagnostic Imaging/methods ; Disease Management ; Disease Susceptibility ; Dopamine/metabolism ; Energy Metabolism ; Fluorodeoxyglucose F18 ; Gene Expression Regulation ; Genetic Predisposition to Disease ; Humans ; Magnetic Resonance Imaging ; Multimodal Imaging ; Neurotransmitter Agents/metabolism ; Parkinson Disease/blood ; Parkinson Disease/diagnosis ; Parkinson Disease/etiology ; Parkinson Disease/metabolism ; Positron-Emission Tomography ; Prodromal Symptoms ; Severity of Illness Index |
Chemical Substances | Biomarkers ; Neurotransmitter Agents ; Fluorodeoxyglucose F18 (0Z5B2CJX4D) ; Dopamine (VTD58H1Z2X) |
Language | English |
Publishing date | 2021-09-16 |
Publishing country | England |
Document type | Journal Article ; Review |
ZDB-ID | 1283676-x |
ISSN | 1528-3658 ; 1076-1551 |
ISSN (online) | 1528-3658 |
ISSN | 1076-1551 |
DOI | 10.1186/s10020-021-00327-x |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 4456: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.